Introduction
Bone loss consequent to allogeneic stem cell transplantation (allo-SCT) has been described by several investigators [1] [2] [3] [4] [5] [6] as being more persistent and severe at cortical bone (femoral neck) when compared to trabecular sites (lumbar spine). 4, 7 Damaging effects on bone mass were attributed to hypogonadism, immunosuppressive and myeloablative treatments, immobilization, increased cytokine release, reduced dietary intake and metabolic alterations of calcium and vitamin D. 5, 6 One of the most important risk factors for bone loss is precocious ovarian failure (POF), which is a common allo-SCT sequela. [8] [9] [10] Calcium and vitamin D supplementation and hypogonadism replacement are commonly used in clinical practice after SCT, while bisphosphonates are added only in patients with osteoporosis. Little information is available so far on the effects of preventive or therapeutic intervention on post-transplant bone loss; 1, [11] [12] [13] no systematic evaluation has been performed to compare the activity of different agents to prevent or treat osteoporosis following allo-SCT. Antireabsorptive treatments have been shown to improve bone mineral density (BMD) and decrease the rate of fractures in postmenopausal and glucocorticoid-induced osteoporosis. [14] [15] [16] [17] The evaluation of these treatments in transplanted patients is difficult, because of frequent poor condition and of the simultaneous presence of other complications, including acute and chronic graft-versushost disease (a-and cGVHD). Liver, skin and gastrointestinal tract are the most common localization of cGVHD 18 and in the active phase may represent a contraindication for the use of oral or trans-dermal therapies; even a mild cGVHD may reduce gastrointestinal or dermal drug absorption. Furthermore, allo-SCT patients usually run into long-lasting and complex therapeutic regimens in order to prevent or treat other complications; thus, the management of osteoporosis can be difficult in some of them.
The present study was aimed at investigating the 12-month effects of various antiresorptive treatments on lumbar and femoral BMD and bone turnover markers in female patients with ovarian failure and low BMD following allo-SCT for hematological malignancies.
Patients and methods
Patients and study design A total of 60 women who had undergone allogeneic SCT at our Institution were enrolled in this study. Persistent amenorrhea occurred in all of them, as a consequence of chemotherapy. POF was diagnosed when gonadotropin levels were in the menopausal range and estradiol below the normal range of fertile women.
All women were evaluated for BMD at the lumbar spine (LS) and femoral neck (FN), body mass index (BMI, kg/m 2 ), serum osteocalcin and urinary hydroxyproline excretion, after a median period of 4 months (range, 3-7) from transplant. Endocrine parameters regarding the reproductive function were also investigated. After the initial evaluation, the patients were divided randomly into four groups of 15 women each. All patients received calcium 1000 mg and vitamin D 800 IU supplementation, administered orally once daily, between 1900 and 2000. Group 1 received only calcium and vitamin D during the whole observational period. In group 2, estradiol 2 mg daily and dihydroprogesterone 10 mg for 14 days a month were added for 12 consecutive cycles. Group 3 was treated with risedronate (35 mg weekly, orally) for 12 months and group 4 by zoledronic acid at the dose of 4 mg intravenous (i.v.) every 28 days for 3 consecutive months. The four groups were all similar in age, BMI, underlying disease, time elapsed from transplant, amenorrhea duration and cGVHD features ( Table 1) .
The determination of densitometry and bone turnover markers was repeated 12 months after the first evaluation. None of the participants had been given previous treatments for osteoporosis. Written informed consent was obtained from all of the patients in accordance with the institutional guidelines; the study was designed in accordance with the Helsinki II Declaration on treatment of human subjects.
Transplantation procedure
All patients had been successfully allo-transplanted with unmanipulated marrow from a HLA identical sibling. Leukemia was the most common indication for allo-SCT. All patients had undergone conditioning with the BU-CY2 regimen (busulfan 16 mg/kg, cyclophosphamide 120 mg/kg) and had received cyclosporine A (CsA) (1 mg/kg/day by continuous i.v. infusion from day À1 to day þ 20 and then 8 mg/kg/day orally) plus short-course methotrexate 10 mg/m 2 on days þ 1, þ 3 and þ 6) as prophylaxis for GVHD. No patient had received radiation therapy. Patients with a-and cGVHD had been treated by methylprednisone (2 or 1 mg/kg/day for 15 days in patients with aGVHD and cGVHD, respectively) and CsA (5 mg/ kg/day) before the first evaluation of bone status. During the study, 53% of patients developed or had persistent cGVHD requiring immunosuppressive therapy as above described. Since a significant correlation between corticosteroid treatment and bone damage was found at the initial evaluation, steroids were avoided whenever possible thereafter. During the study period, cGVHD was treated by CsA þ mycophenolate mofetil at a dose of 30 mg/kg/day; low-dose corticosteroids were continued in addition to these immunosuppressants in 11 patients only. The median cumulative dose of steroids given to this cohort of patients prior to study entry was equivalent to 6.4 g of prednisone (range, 0.9-20) for 3-36 months, while the average dose administered during the study was 1.370.9 g for 3-10 months. The number of patients treated by steroids and the Table 1 Clinical features of 60 transplanted female patients long-term surviving after allogeneic SCT dose used during the study was similar among the four groups.
Gonadal status assessment
At study entry, all the women underwent measurement of serum FSH, LH, 17-b-estradiol, testosterone and dehydroepiandrosterone-sulfate (DHEA-S) in a single sample taken at 0800. The same parameters were re-evaluated after 6 and 12 months. All measurements were performed by commercially available kits: FSH and LH with radioimmunoassay (RIA, Biodata, Rimini, Italy), testosterone, DHEA-S and estradiol using Immulite, solid-phase chemoluminescent enzyme immunoassay (DPC, Los Angeles, CA, USA).
Bone metabolism assessment Serum calcium, phosphorus, creatinine, bone alkaline phosphatase (ALP), intact parathyroid hormone (iPTH) and osteocalcin were determined in blood samples drawn at initial evaluation and after 6 and 12 months. Blood samples were collected in the morning after a 12-h fast. Urinary calcium, phosphorus and hydroxyproline were assayed on a 24-h urinary collection. Standard dietary restrictions were observed by all the individuals tested, starting 5 days prior to urinary collection. Intact PTH and serum osteocalcin levels were measured by RIA (Nichols Institute Diagnostics, CA, USA), the detection limit of the latter being 0.35 mg/l. Bone alkaline phosphatase was assayed by a direct immunoradiometric assay (Ostease, Hybritech, San Diego, CA, USA). Hydroxyproline excretion was measured by high-pressure liquid chromatography. Blood chemistry profile, including Ca, P, ALP, urinary Ca excretion and creatinine levels, were analyzed using a standard autoanalyzer.
Bone density and fracture assessment Bone density was determined by dual-energy X-ray absorptiometry (DEXA) at the lumbar spine (L1-L4) and femoral neck (FN), using Hologic QDR 1000 densitometer (Hologic Inc., Waltham, MA, USA). Individual BMD values were expressed as g/cm 2 and T-and Z-scores. Quality control was performed by daily scanning of an anthropomorphic spine phantom. The coefficient of variation was 1.8% for the LS and 2.2% for the FN. The reference population adopted in this study was the international pooled sample provided by the manufacturer; their data, however, did not differ significantly from those obtained on a local sample in a study performed when the device was set up. 19 Standard spinal radiography in anterior-posterior and lateral positions of vertebrae T4-L4 was performed in all patients at baseline and after 12 months. A subclinical fracture was defined as a 20% difference in anteroposterior, middle-posterior or posterior-posterior adjacent ratio. 20 
Statistical analysis
Data are reported as mean7s.d. unless otherwise specified.
The normal data distribution was tested by the WilkShapiro's test. Statistical analysis was performed by the Student's t-test for paired and unpaired data, as appropriate, for comparison between groups treated by different regimens. At pretreatment evaluation, the association between BMD values, immunosuppressive treatment duration and cumulative doses, and amenorrhea period were assessed by linear regression. Comparison of the variables within the same group was performed by the Friedman test. The significance was set at 5%.
Results

Clinical features and gonadal status
Clinical features at study entry, underlying malignancies and details on previous treatments are summarized in Table 1 . No statistically significant differences emerged among the four group for all findings listed. Women who did not undergo HRT did not experienced recovery of spontaneous menstrual cycles during the observational period. None of the women from group 2 reported menstrual cycles within 60 days after HRT withdrawal at the end of the study, their gonadotropins and estradiol being still in the postmenopausal range.
Baseline evaluation of bone turnover and BMD after SCT Gonadotropin values were in the menopausal range, while estradiol, testosterone and DHEA-S were significantly lower than the normal range for reproductive aged women. Baseline endocrine parameters, BMD values at both skeletal sites and bone turnover markers were similar in all groups of patients ( Table 2 ). According to the WHO criteria, 21 osteoporosis was diagnosed in four patients of group 1, five of group 2, five of group 3 and six of group 4. Baseline lumbar BMD correlated inversely with the duration of amenorrhea (r ¼ À0.47; P ¼ 0.045). Serum osteocalcin correlated with baseline lumbar BMD (r ¼ 0.61; P ¼ 0.048). A borderline correlation was present between lumbar BMD and cumulative dose of corticosteroids used prior to the study entry (r ¼ À0.49; P ¼ 0.05).
Treatment effects on endocrine parameters, bone turnover and BMD Mean gonadotropin, estradiol, testosterone and DHEA-S levels did not change significantly in groups 1, 3 and 4. Gonadotropins decreased (FSH by 60%, LH by 64%) and estradiol increased (by 387%) in group 2 during HRT (Po0.0001, all), whereas testosterone and DHEA-S did not change; nevertheless, gonadotropins still remained above and estradiol below their normal ranges for reproductive aged women.
There were no significant changes in BMI, serum levels of calcium, phosphorus, albumin, calcium urinary excretion and iPTH in any group during the 12-month observation period.
In groups 3 and 4 hydroxyproline excretion significantly decreased at 3, 6 and 12 months, when compared with baseline values (Po0.001, Figure 1 ). Bone alkaline phosphatase and osteocalcin did not change in groups 1, 2 and 3; they were found slightly but significantly increased in group 4 (P ¼ 0.038 and P ¼ 0.032, respectively).
At baseline, two women in group 3 and three in group 4 had X-ray findings of subclinical vertebral fractures. Two incident subclinical vertebral fractures in group 1 and one in group 2 were detected at the 12th month radiological evaluation of the spine. No nonvertebral fracture occurred during the observation period. Antireabsorptive treatments after allogeneic SCT L Tauchmanovà et al A significant decrease in lumbar and femoral BMD was observed in group 1 (À4.372.3 and À4.271.6%, P ¼ 0.046, Figure 2 ), while a slight not significant decrease was found in group 2 (À3.171.4 and À3.371.5%). Risedronate treatment significantly increased lumbar BMD (5.872.1%; Po0.035) and prevented bone loss at femoral neck (1.371.2%; P ¼ 0.6 vs baseline). Zoledronic acid increased significantly both lumbar and femoral BMD (8.677%; Po0.01 and 5.472.2%; Po0.039, vs baseline, respectively).
After the 12-month treatment period, the changes in BMD between group 4 and groups 1-2 were significant at both LS and FN (Po0.00001). Even changes between group 3 and groups 1-2 were significant at both LS and FN (Po0.00001). Only the difference in FN BMD was significant between groups 3 and 4 (Po0.0001).
The inter-group difference in absolute BMD values at 12 months was not significant.
Treatment adverse effects
No patient dropped out during the 12-month treatment in any group. After HRT introduction in group 2, five women suffered from a moderate headache and six from breast tenderness. These disorders disappeared invariably within the third month of treatment. Three patients in group 3 complained about mild-to-moderate gastric pain, which was well controlled by addition of antacid treatment.
Flu-like symptoms, including myalgia, body temperature increase (o37.81C) and nausea, occurred in 12 women (80%) treated by zoledronic acid; these symptoms were well controlled using 15 mg prednisone as a premedication, 1 h before zoledronic acid infusion.
Kidney and liver function was carefully monitored in all women every 2 months and did not change over the whole observation period.
Discussion
This is a controlled study comparing different antireabsorptive treatments in a population of hypogonadal women after allo-SCT. This study clearly demonstrates that the interventions commonly used for prevention of bone loss in the general population have no protective effects in hypogonadal transplanted women. 1, 22 In our experience, the supplementation of calcium and vitamin D, alone or together with the correction of hypogonadism, did not reverse bone loss in women after allo-SCT. The reasons for this may be related to the chronic and multifactorial nature of post-SCT bone loss. Indeed, age, time since SCT, degree of hypogonadism, presence of cGHVD and subsequent steroid treatments are all related in some way to bone loss. [1] [2] [3] [4] [5] 13 Moreover, cytotoxic drugs have harmful effects on bone 23 and the transplant procedure itself negatively influences bone mass, mainly throughout 'cytokine storm', GVHD and persistent reduction of the regenerative capacity of the osteoblastic bone marrow lineage. 3, 24, 25 Considering together our results and the existing data on the ineffectiveness of common intervention in preventing bone loss, 22 transplanted patients need to be treated by more potent and specific agents.
Although calcium and vitamin D supplementation is insufficient by itself, it is necessary after SCT because gastrointestinal absorption of these agents is reduced and metabolism is altered. 2, 4 All our patients were replaced with calcium and vitamin D during the whole observational period.
Although virtually all women experience transient or permanent amenorrhea consequent to allo-SCT, few data are available on systemic effects, type and administration schedule of HRT. In women after the physiological menopause, HRT has been widely shown to be effective in relieving the multiple symptoms of gonadal failure, including osteoporosis. 14, 15 HRT was reported as effective in the treatment of post-transplant bone loss in a study by Castelo-Branco. 11 We cannot confirm these results, since we could not find any improvement of BMD during the 12-month HRT administration; in fact, bone loss continued. Vasomotor symptoms and urogenital dryness disappeared in all women, whereas endocrine parameters only improved. We chose the most physiological and easy to use schedule: one pill every day for 28 days in an oral combined sequential schedule. There are at least three possible explanations for the lack of HRT's protective effects in our patients: (i) young women with POF may require doses higher than those used for the treatment of physiological menopause; (ii) bone marrow transplanted women may have reduced intestinal absorption of the drugs due to persistent gastrointestinal system damage by the previous chemotherapy or to gastrointestinal cGVHD (which could be mild and unrecognized); (iii) the cause of post-transplant bone loss could be only partially related to estrogen deficiency.
In any case, the management of HRT in allo-transplanted women is not easy, since about 50% of patients develop chronic GVHD. HRT is contraindicated in women with abnormal liver function due to cGVHD. Few data are available on HRT use in women who had undergone SCT; this treatment can be considered safe in absence of active acute or cGVHD. There is evidence that HRT does not increase the risk of cGVHD exacerbation and prevents some adverse effects of long-lasting ovarian failure in young women. 26, 27 Oral bisphosphonates proved to be effective for treating postmenopausal and glucocorticoid-induced osteoporosis. 14, 15, 17 In a previous study from our group, a 12-month treatment with a daily dose of 5 mg of risedronate increased BMD by 5.9% at the LS and prevented bone loss at the femoral neck in a mixed population of allo-transplanted patients. 12 Nevertheless, gastrointestinal GVHD can impaired absorption of oral bisphosphonates, which are characterized by a low absorption even in the general population. 28, 29 Furthermore, these agents are contraindicated in immobilized patients. Bisphosphonates (i.v.) proved to be effective in the treatment of postmenopausal and glucocorticoid-induced osteoporosis, 30, 31 although their principal indications are hypercalcemia management in cancer patients and prevention and treatment of bone metastases of various malignancies. In our experience, zoledronic acid was the only agent, which improved bone density at cortical rich bone in hypogonadal females. This drug also produced beneficial effects on lumbar and femoral BMD in a mixed population of hypogonadal/ eugonadal allo-transplanted men and women. 13 In our study, zoledronic acid was given as three consecutive doses of 4 mg each in order to obtain a rapid and consistent effect on bone mass. Several infusion protocols have been used for the treatment of osteoporosis, but no standard regimen is currently recommended. In different patient populations, the total dose of zoledronic acid administered over the period of one year ranged from 4 mg in menopausal women 30 to 16 mg in men with nonmetastatic prostate cancer during androgen deprivation. 16 These regimens caused a BMD increase that ranged from 4.3 to 5.6% at LS and from 2.7 to 3.1% at FN. A significant persistent suppression of bone turnover markers was also documented in postmenopausal women. 30 An important aspect of zoledronic acid is the possibility of administration as intermittent short-lasting infusion, which can be easily added to the complex therapeutic regimens generally used in transplanted patients.
Bisphosphonates are currently the most effective inhibitors of bone resorption; they exert a direct effect on osteoclasts, inhibiting their bone-resorbing activity, 32 inducing apoptosis [32] [33] [34] and blocking their precursor proliferation. 34, 35 In addition, recent in vitro evidence has been accumulated on anabolic bone effects of bisphosphonates. They directly enhance osteoblast proliferation and promote a differentiation of osteoprogenitor cells towards the osteoblastic pathway. 36, 37 Bisphosphonates also prevent osteoblast apoptosis 38, 39 and upregulate production of extracellular matrix proteins by osteoblasts. 35 These effects have been reported for different members of the bisphosphonate family, including zoledronic acid, pamidronate, neridronate, alendronate and risedronate. 34, 40, 41 In a previous study, we documented that bone effects of zoledronic acid in transplanted patients were associated with a significant improvement in the regenerating capacity of osteogenic stromal lineage precursors. Similar findings have also been reported for risedronate in vitro: risedronate stimulated osteoblast proliferation in a human trabecular bone culture model. This effect was more evident and sustained over a wide range of time periods and drug concentration when risedronate was compared with alendronate. 40 The positive effects on osteoblasts may be particularly important in allo-transplanted patients, since previous evidence indicated a persistently reduced regenerative and functional capacity of osteoblast precursors. 3, 23, 24, 41, 42 Although we did not evaluate osteoblastic lineage behavior in patients treated by risedronate, it is likely that BMD improvement produced by risedronate is at least in part related to its anabolic effects, in analogy with what we documented with zoledronic acid. 13 As a matter of fact, the improvement observed in the patients treated by bisphosphonates was highly significant at both LS and FN. A significant decrease in hydroxyproline excretion was also observed in the groups treated by bisphosphonates. The increase in serum bone alkaline phosphatase and osteocalcin was just at the limit of statistical significance only in the zoledronate group. When concerning with bone formation markers in post-transplant osteoporosis, controversial results were reported in serum osteocalcin levels during bisphosphonate treatment. 43, 44 Side effects of the treatments employed were generally mild and well controlled by appropriate premedications. No alteration in kidney function was detected at any time point during the study, and liver enzymes did not worsen during the treatment period.
No conclusion can be made about fracture risk reduction because this study is not sufficiently powerful to evaluate fracture incidence as a clinical end point. Whether any treatment is able to reduce fracture risk after allo-SCT still remains to be determined.
In conclusion, persistent multifactorial bone loss in allotransplanted patients needs a specific and careful treatment. Neither calcium plus vitamin D supplementation nor its association with HRT were able to prevent bone loss in young adult hypogonadal women after allo-SCT. Bisphosphonates are currently the only treatment able to prevent and treat bone demineralization in this particular population of patients. Weekly oral risedronate and monthly i.v. zoledronic acid infusion were easily manageable and effective in increasing densitometric values at trabecular skeletal site. Zoledronic acid was the only therapy that improved femoral BMD. At least part of these effects can be ascribed to the bisphosphonate ability in reversing the persistent post-transplant reduction of clonogenic fibroblast progenitors belonging to the osteogenic stromal lineage. Currently, the choice between oral or i.v. bisphosphonate therapy in patients who had undergone allogeneic SCT should be made on the basis of individual clinical conditions, including presence, grading and localization of GVHD, and prevalent site of bone loss. The evaluation of cost-effectiveness requires data on fracture prevention, which still need to be produced. In any case, larger studies and prolonged follow up are needed to draw guidelines for bone loss prevention and treatment in stem cell transplanted patients.
